← Trials/Trial dossier/NCT03466021
Effects of Liraglutide in Chronic Obstructive Pulmonary Disease
Effects of GLP-1 Receptor Agonist Treatment on Pulmonary Function and Quality of Life in Obese Patients With Chronic Obstructive Pulmonary Disease.
Lead sponsor
Assets
GLP-1 / incretin class catch-all / Liraglutide
Listed sites
2
Recruiting sites
—
Enrollment
40
actual
Study population
Obesity / overweight, Pulmonary Disease, Chronic Obstructive
Key I/E criterion
•BMI ≥27
Primary endpoint
•Transition Dyspnea Index (TDI)
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
1. Informed consent obtained before any trial-related activities
2. COPD as defined by FEV1/FVC<70% after maximal broncho-dilatation and in accordance with the Gold guidelines 2017 (25)
3. Previous smoking of ≥ 20 pack-years
4. Overweight defined as BMI > 27 kg/m2
5. Age 30 - 75 years
6. Women of childbearing potential must use a safe anti-contraceptive method
Exclusion criteria
1. Chronic treatment with systemic steroids (inhalation steroids allowed)
2. Current smokers
3. Diabetes mellitus type 1 and type 2 as defined by current or previous treatment with antidiabetic medications of any kind or HbA1c ≥ 48mmol/mol
4. Severe hepatic disease (Alanine transferase > 3 x UNL)
5. Severe impaired renal function (eGFR < 30ml/min)
6. Congestive heart disease New York Heart Association (NYHA) class 3-4
7. History of acute or chronic pancreatitis
8. History of cholecystitis or cholecystolithiasis
9. Pregnant or breastfeeding women
10. Known bronchial asthma or interstitial lung disease
11. Family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma
12. Large goiter or plasma-calcitonin > 50ng/ml
Endpoints (20)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
1 endpointBody weight
Time frame:44 weeks
Body weight, absolute change (kg)
change from baseline, improvement
Heart failure
1 endpoint6 minutes walking test
Time frame:44 weeks
6-minute walk distance
change from baseline, improvement
Cardiometabolic biomarkers
2 endpointsCRP
Time frame:44 weeks
hs-CRP, change
change from baseline, improvement
LOINC 30522-7
IL-6
Time frame:44 weeks
change from baseline, improvement
Patient-reported / QoL
3 endpointsCAT-score
Time frame:44 weeks
change from baseline, improvement
SF-36
Time frame:44 weeks
SF-36 total
descriptive, improvement
Epworth score
Time frame:Twice during 44 weeks
change from baseline, improvement
Safety / tolerability / PK
1 endpointChanges in use of bronchodilator drugs and anti-inflammatory drugs
Time frame:44 weeks
percent change from baseline, descriptive
componentsbronchodilator drug use change, anti inflammatory drug dose change
Other clinical outcomes
8 endpointsTransition Dyspnea Index (TDI)
Time frame:40 weeks
change from baseline, improvement
Diffusion capacity of the lung for carbon monoxide (DLCO)
Time frame:44 weeks
descriptive
FEV1/FVC
Time frame:44 weeks
ratio, improvement
Total lung capacity (TLC)
Time frame:44 weeks
change from baseline, improvement
Residual volume (RV)
Time frame:44 weeks
change from baseline, descriptive
Number of COPD exacerbations
Time frame:44 weeks
event count, event
Apnea/hypopnea index (AHI)
Time frame:Twice during 44 weeks
AHI, change
change from baseline, improvement
Oxygen desaturation index (ODI)
Time frame:Twice during 44 weeks
change from baseline, improvement
Other (unclassified)
4 endpointsMCP-1
Time frame:44 weeks
change from baseline, improvement
Maximal standard uptake value (SUV max)
Time frame:Twice over 44 weeks
descriptive
Mean standard uptake value (SUV mean)
Time frame:Twice over 44 weeks
descriptive
Total lesion glycolysis (TLG)
Time frame:Twice over 44 weeks
descriptive
Publications (1)
Bibliography
Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.
Registry references + supporting bibliography
- BMC research notes2024 Jun 20PMID38902794doi:10.1186/s13104-024-06820-wvia clinicaltrials gov reference derived + pubmed nct search
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.